Fluoride Action Network

Clinical Trial for Fluoride Supplementation to Pregnant Women

Fluoride Action Network - Clinical Trial - updated September 23, 2017

According to the website at ClinicalTrials.gov, a study titled Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being was proposed to take place at Johns Hopkins Hospital in Baltimore, Maryland, with a start date of October 2015. Even though the website states the trial is still recruiting women, it’s unclear whether it has begun.

There would be two groups of women involved in the trial:

  1. Those given a prenatal vitamin-mineral containing 3 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
  2. The control group receiving 0 mg fluoride.

Purpose of Trial:

The purpose of this study is to determine whether fluoride supplementation during pregnancy is effective in extending the length of gestation and improving overall perinatal well-being.

Detailed Description of the Trial:

The Centers for Disease Control and Prevention (CDC) reports that preterm birth affected about 1 in 10 infants born in the United States in 2015. These statistics emphasize the significance of implementing a safe and effective therapy into routine clinical care aimed at reducing the rate of preterm birth. There has been evidence to suggest that fluoride supplementation to women during pregnancy can provide other medical benefits, in addition to a reduction in dental caries.

Fluoride is recognized by the Food and Nutrition Board (F&NB) of the American Academy of Sciences and the Food & Drug Administration (FDA) as an essential ion due to its association with a reduction in dental caries.

Upon entering the body, fluoride is taken up into the bones/calcified tissues, and excreted by the kidneys. When supplied during pregnancy in small aliquots, as with water fluoridation, the fluoride is likely taken up in the mother’s bones and excreted by her kidneys so rapidly, that the fetus is denied a meaningful amount of fluoride, unless it is supplied in a pulse dose by supplement. The Institute of Medicine’s Food and Nutrition Board recommends 3 mg/day for Adequate Intake in pregnancy and deems 10 mg/day as the Upper Limit.

After several papers elucidating an association between poor dentition, periodontal disease, and preterm birth, subsequent RCT’s of regular periodontal scaling and treatment during pregnancy are still inconclusive in regards to preterm birth.

The investigaors hypothesize that fluoride supplementation during pregnancy may have a beneficial effect on the natural microbiome of the maternal oral cavity and genital tract, capable of protecting against transient bacteremia and ascending infection, respectively, which are known antecedents to both preterm labor and preterm premature rupture of membranes. The research team predicts that the testing and analysis of specimens collected will demonstrate microbiome changes toward a more favorable profile not associated with preterm birth.

The proposed randomized, double-blinded, placebo-controlled clinical trial aims to confirm the efficacy of fluoride supplementation in pregnancy to extend length of gestation and increase overall perinatal well-being, and to confirm transplacental transfer of supplemental fluoride. This research may also identify other beneficial maternal and neonatal outcomes associated with the administration of fluoride during the perinatal period by attempting to characterize and compare the microbiomes of the maternal oral cavity and genital tracts between supplemented and unsupplemented gravidas.

Primary Outcome Measures:

  • Length of gestation [ Time Frame: Participants will be followed from the time of study enrollment until delivery, up to 30 weeks total in the study ]
    the length of gestation will be measured in weeks at time of delivery

Time Frame of Trial:

  • Estimated Enrollment: 1500
    Study Start Date: October 2015
    Estimated Study Completion Date: October 2019
    Estimated Primary Completion Date: October 2019 (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women who are between 10-20 weeks gestational age at the time of recruitment
  • Delivery at Johns Hopkins Hospital or Johns Hopkins Bayview Medical Center

Exclusion Criteria:

  • Use of prescription strength, high dose fluoride products (greater than 0.76% of fluoride), prescribed by a dental professional (toothpastes, mouthwashes, topical treatments). All over-the-counter toothpaste and mouthwash products are acceptable to use.
  • Occupational exposure to fluoride.
  • The daily amount of fluoride ingested should not exceed 10 mg/day, according to the Institute of Medicine and the FDA. Any participants consuming amounts of fluoride close to 10 mg/day will be excluded.

Sponsors and Collaborators: Johns Hopkins University

Principal Investigator: Irina Burd, MD, PhD, Johns Hopkins University, Baltimore, Maryland

*For more information go to https://clinicaltrials.gov/ct2/show/study/NCT02536352